C. Finley Baba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
C. Finley Baba has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Daniel Grossman
Advancing New Standards in Reproductive Health (ANSIRH), Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, CA
5 shared publicationsM. Antonia Biggs
Advancing New Standards in Reproductive Health (ANSIRH), Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, CA
4 shared publications- M. Antonia Biggs
Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, Oakland, CA 94612, USA
3 shared publications - Sarah Averbach
Center for Gender Equity and Health, University of California, San Diego, San Diego, USA
3 shared publications - Shelly Kaller
Advancing New Standards in Reproductive Health, University of California, San Francisco, Oakland, California
3 shared publications - Alejandra Ramm
University of Valparaíso
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e91842
Perceived Importance of Abortion Care Features and Access to Telehealth Technologies Among Medication Abortion Patients by Abortion Care Model: Cross-Sectional Analysis of a Prospective Cohort Study
Background: Medication abortion accounts for the majority of abortions in the United States, driven in part by the growth in access to telehealth provision of medication abortion. While research indicates high patient satisfaction with telehealth medication abortion care, research on care preferences of patients who use medication abortion remains understudied. Understanding these preferences is essential to informing evidence-based policies that enable people to access person-centered abortion services that meet their values, preferences, and needs. Objective: The aim of this study is to compare the abortion care features rated as most important among patients receiving medication abortion via telehealth vs in-person care and to assess participants’ access to technologies required for telehealth care. We hypothesized that participants receiving telehealth care would place greater importance on features supporting limited in-person clinic interaction. Methods: From May 2021 to March 2023, we surveyed participants (≤70 d of gestation, English or Spanish speakers, aged ≥15 y) obtaining medication abortion at 4 organizations providing care in 6 US states. Participants rated the importance of 12 abortion care features (ie, getting care at home, convenience, cost, safety, effectiveness, and privacy) and described access to technologies required for telehealth. We used bivariable logistic and ordinal regressions with robust SEs to assess whether features rated as “extremely important” differed by the medication abortion model received (telehealth vs in-person). Results: Among 1017 patients approached, 876 were eligible, 583 participants enrolled, 487 initiated a survey, 477 (242 telehealth and 235 in-person) completed survey questions regarding access to technologies for telehealth, and 397 completed questions about abortion care features. Across groups, the features most often rated as “extremely important” included effectiveness (340/397, 85.6%), safety (326/397, 82.1%), timeliness (307/397, 77.3%), and privacy (165/211, 78.2%), with no significant differences ( P >.05) between groups. Compared to in-person participants, telehealth participants were more likely to report getting care at home (65.9% vs 43.5%; odds ratio [OR] 2.48, 95% CI 1.57‐3.89; P <.001) and having a medication abortion (62.1% vs 51.1%; OR 1.58, 95% CI 1.11‐2.23; P =.01) as extremely important. They were less likely to report having an in-person meeting with a clinician (16.1% vs 45.7%; OR 0.23, 95% CI 0.19‐0.26; P <.001) and ultrasonography (15.2% vs 38.2%; OR 0.28, 95% CI 0.20‐0.40; P <.001) as extremely important. Abortion care features rated as extremely important were sometimes discordant with the care received. Almost all participants had access to the technologies required for telehealth. Conclusions: While telehealth abortion services offer many features that people find important, the availability of both telehealth and in-person abortion care remains critical to ensuring that care aligns with patient preferences. In addition to efforts focused on expanding access to telehealth medication abortion services, advocates and policymakers should continue their work to ensure access to in-person care for those who need or prefer this model.
- 15 July 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e91842
Open AccessPerceived Importance of Abortion Care Features and Access to Telehealth Technologies Among Medication Abortion Patients by Abortion Care Model: Cross-Sectional Analysis of a Prospective Cohort Study
Background: Medication abortion accounts for the majority of abortions in the United States, driven in part by the growth in access to telehealth provision of medication abortion. While research indicates high patient satisfaction with telehealth medication abortion care, research on care preferences of patients who use medication abortion remains understudied. Understanding these preferences is essential to informing evidence-based policies that enable people to access person-centered abortion services that meet their values, preferences, and needs. Objective: The aim of this study is to compare the abortion care features rated as most important among patients receiving medication abortion via telehealth vs in-person care and to assess participants’ access to technologies required for telehealth care. We hypothesized that participants receiving telehealth care would place greater importance on features supporting limited in-person clinic interaction. Methods: From May 2021 to March 2023, we surveyed participants (≤70 d of gestation, English or Spanish speakers, aged ≥15 y) obtaining medication abortion at 4 organizations providing care in 6 US states. Participants rated the importance of 12 abortion care features (ie, getting care at home, convenience, cost, safety, effectiveness, and privacy) and described access to technologies required for telehealth. We used bivariable logistic and ordinal regressions with robust SEs to assess whether features rated as “extremely important” differed by the medication abortion model received (telehealth vs in-person). Results: Among 1017 patients approached, 876 were eligible, 583 participants enrolled, 487 initiated a survey, 477 (242 telehealth and 235 in-person) completed survey questions regarding access to technologies for telehealth, and 397 completed questions about abortion care features. Across groups, the features most often rated as “extremely important” included effectiveness (340/397, 85.6%), safety (326/397, 82.1%), timeliness (307/397, 77.3%), and privacy (165/211, 78.2%), with no significant differences ( P >.05) between groups. Compared to in-person participants, telehealth participants were more likely to report getting care at home (65.9% vs 43.5%; odds ratio [OR] 2.48, 95% CI 1.57‐3.89; P <.001) and having a medication abortion (62.1% vs 51.1%; OR 1.58, 95% CI 1.11‐2.23; P =.01) as extremely important. They were less likely to report having an in-person meeting with a clinician (16.1% vs 45.7%; OR 0.23, 95% CI 0.19‐0.26; P <.001) and ultrasonography (15.2% vs 38.2%; OR 0.28, 95% CI 0.20‐0.40; P <.001) as extremely important. Abortion care features rated as extremely important were sometimes discordant with the care received. Almost all participants had access to the technologies required for telehealth. Conclusions: While telehealth abortion services offer many features that people find important, the availability of both telehealth and in-person abortion care remains critical to ensuring that care aligns with patient preferences. In addition to efforts focused on expanding access to telehealth medication abortion services, advocates and policymakers should continue their work to ensure access to in-person care for those who need or prefer this model.
- Open Access
- 10 April 2026
- Published by Elsevier in Contraception
- Vol. 161, 111459
Satisfaction with and feasibility of no-test telehealth medication abortion vs in-person care with ultrasound in the United States
- 10 April 2026
- Published by Elsevier in Contraception
- Vol. 161, 111459
Open AccessSatisfaction with and feasibility of no-test telehealth medication abortion vs in-person care with ultrasound in the United States
- Open Access
- 23 April 2024
- Published by Elsevier in Women's Health Issues
- Vol. 34 (4) , 381-390
Interest in and Support for Alternative Models of Medication Abortion Provision Among Patients Seeking Abortion in the United States
- 23 April 2024
- Published by Elsevier in Women's Health Issues
- Vol. 34 (4) , 381-390
Open AccessInterest in and Support for Alternative Models of Medication Abortion Provision Among Patients Seeking Abortion in the United States
- Open Access
- 25 April 2023
- Published by Elsevier in Women's Health Issues
- Vol. 33 (5) , 481-488
Perspectives on Alternative Models of Medication Abortion Provision Among Abortion Patients in the United States
- 25 April 2023
- Published by Elsevier in Women's Health Issues
- Vol. 33 (5) , 481-488
Open AccessPerspectives on Alternative Models of Medication Abortion Provision Among Abortion Patients in the United States
- Open Access
- 30 July 2022
- Published by Elsevier in Women's Health Issues
- Vol. 32 (6) , 571-577
“No Big Deal”: A Qualitative Study of Pharmacists’ Perspectives on Dispensing Mifepristone for Medication Abortion
- 30 July 2022
- Published by Elsevier in Women's Health Issues
- Vol. 32 (6) , 571-577
Open Access“No Big Deal”: A Qualitative Study of Pharmacists’ Perspectives on Dispensing Mifepristone for Medication Abortion
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 61 (6) , 785-794.e1
Pharmacists’ knowledge, perspectives, and experiences with mifepristone dispensing for medication abortion
- 1 November 2021
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 61 (6) , 785-794.e1
Open AccessPharmacists’ knowledge, perspectives, and experiences with mifepristone dispensing for medication abortion
- Open Access
- 10 March 2021
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 137 (4) , 613-622
Medication Abortion With Pharmacist Dispensing of Mifepristone
OBJECTIVE: To estimate effectiveness and acceptability of medication abortion with mifepristone dispensed by pharmacists. METHODS: We conducted a prospective cohort study at eight clinical sites and pharmacies in California and Washington State from July 2018 to March 2020. Pharmacists at participating pharmacies underwent a 1-hour training on medication abortion. We approached patients who had already been evaluated, counseled, and consented for medication abortion per standard of care. Patients interested in study participation gave consent, and the clinician electronically sent a prescription to the pharmacy for mifepristone 200 mg orally, followed 24–48 hours later by misoprostol 800 micrograms buccally. Participants were sent web-based surveys about their experience and outcomes on days 2 and 14 after enrollment and had routine follow-up with study sites. We extracted demographic and clinical data, including abortion outcome and adverse events, from medical records. We performed multivariable logistic regression to assess the association of pharmacy experience and other covariates with satisfaction. RESULTS: We enrolled 266 participants and obtained clinical outcome information for 262 (98.5%), of whom two reported not taking either medication. Of the 260 participants with abortion outcome information, 252 (96.9%) and 237 (91.2%) completed day 2 and 14 surveys, respectively. Complete medication abortion (primary outcome) occurred for 243 participants (93.5%, 95% CI 89.7–96.1%). Four participants (1.5%, 95% CI 0.4–3.9%) had an adverse event, none of which was serious or related to pharmacist dispensing. In the day 2 survey, 91.3% (95% CI 87.1–94.4%) of participants reported satisfaction with the pharmacy experience. In the day 14 survey, 84.4% (95% CI 79.1–88.8%) reported satisfaction with the medication abortion experience. Those reporting being very satisfied with the pharmacy experience had higher odds of reporting overall satisfaction with medication abortion (adjusted odds ratio 2.96, 95% CI 1.38–6.32). CONCLUSION: Pharmacist dispensing of mifepristone for medication abortion is effective and acceptable to patients, with a low prevalence of adverse events. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03320057.
- 10 March 2021
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 137 (4) , 613-622
Open AccessMedication Abortion With Pharmacist Dispensing of Mifepristone
OBJECTIVE: To estimate effectiveness and acceptability of medication abortion with mifepristone dispensed by pharmacists. METHODS: We conducted a prospective cohort study at eight clinical sites and pharmacies in California and Washington State from July 2018 to March 2020. Pharmacists at participating pharmacies underwent a 1-hour training on medication abortion. We approached patients who had already been evaluated, counseled, and consented for medication abortion per standard of care. Patients interested in study participation gave consent, and the clinician electronically sent a prescription to the pharmacy for mifepristone 200 mg orally, followed 24–48 hours later by misoprostol 800 micrograms buccally. Participants were sent web-based surveys about their experience and outcomes on days 2 and 14 after enrollment and had routine follow-up with study sites. We extracted demographic and clinical data, including abortion outcome and adverse events, from medical records. We performed multivariable logistic regression to assess the association of pharmacy experience and other covariates with satisfaction. RESULTS: We enrolled 266 participants and obtained clinical outcome information for 262 (98.5%), of whom two reported not taking either medication. Of the 260 participants with abortion outcome information, 252 (96.9%) and 237 (91.2%) completed day 2 and 14 surveys, respectively. Complete medication abortion (primary outcome) occurred for 243 participants (93.5%, 95% CI 89.7–96.1%). Four participants (1.5%, 95% CI 0.4–3.9%) had an adverse event, none of which was serious or related to pharmacist dispensing. In the day 2 survey, 91.3% (95% CI 87.1–94.4%) of participants reported satisfaction with the pharmacy experience. In the day 14 survey, 84.4% (95% CI 79.1–88.8%) reported satisfaction with the medication abortion experience. Those reporting being very satisfied with the pharmacy experience had higher odds of reporting overall satisfaction with medication abortion (adjusted odds ratio 2.96, 95% CI 1.38–6.32). CONCLUSION: Pharmacist dispensing of mifepristone for medication abortion is effective and acceptable to patients, with a low prevalence of adverse events. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03320057.